{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:13:29Z","timestamp":1793330009671,"version":"4.5.0"},"reference-count":8,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>We report three obese patients with type 2 diabetes and alcohol-associated liver disease (ALD), including one patient with alcohol use disorder, who exhibited reduced alcohol intake after the initiation of tirzepatide. Although tirzepatide has shown beneficial effects on liver fibrosis in metabolic dysfunction-associated steatohepatitis, its effect on ALD or alcohol intake has not been reported. After the initiation of tirzepatide, all patients demonstrated decreased alcohol consumption, improved liver function, and better metabolic control. These findings suggest that tirzepatide can provide additional benefits for ALD by reducing alcohol intake while improving metabolic risk factors, potentially offering a novel therapeutic option for this high-risk population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Learning points<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1530\/edm-26-0002","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T12:47:48Z","timestamp":1775134068000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":1,"title":["Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity"],"prefix":"10.1530","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1859-0764","authenticated-orcid":true,"given":"Hiroki","family":"Takizawa","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kido Hospital, Niigata, Japan 1"},{"name":"Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kido Hospital, Niigata, Japan 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Suriki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kido Hospital, Niigata, Japan 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Amagane","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Kohdo Hospital, Niigata, Japan 3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"2026081809182847400_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101162","article-title":"Alcohol-associated liver disease: epidemiology and management","volume":"29","author":"Hern\u00e1ndez-\u00c9vole","year":"2024","journal-title":"Ann Hepatol"},{"key":"2026081809182847400_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ueg2.12524","article-title":"Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease","volume":"12","author":"Hagstr\u00f6m","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"2026081809182847400_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"2026081809182847400_bib4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"2026081809182847400_bib5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026081809182847400_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70045","article-title":"Tirzepatide versus semaglutide on weight loss in type 2 diabetes patients: a systematic review and meta-analysis of direct comparative studies","volume":"8","author":"Wen","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"2026081809182847400_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1532076","article-title":"The role of GIPR in food intake control","volume":"16","author":"James-Okoro","year":"2025","journal-title":"Front Endocrinol"},{"key":"2026081809182847400_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamapsychiatry.2018.3079","article-title":"Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials","volume":"76","author":"Falk","year":"2019","journal-title":"JAMA Psychiatry"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2026\/2\/EDM-26-0002.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2026\/2\/EDM-26-0002.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/edm\/article-pdf\/doi\/10.1530\/EDM-26-0002\/519762\/edm-26-0002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/edm\/article-pdf\/doi\/10.1530\/EDM-26-0002\/519762\/edm-26-0002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:18:34Z","timestamp":1787059114000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/edm\/article\/2026\/2\/EDM260002\/77537\/Tirzepatide-reduced-alcohol-use-in-three-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1530\/edm-26-0002","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"EDM260002"}}